From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Conflict and Health
[Accessed 12 July 2014]
http://www.conflictandhealth.com/

Short report
Description of a large measles epidemic in Democratic Republic of Congo, 2010-2013
Mancini S, Coldiron ME, Ronsse A, Ilunga BK, Porten K and Grais RF Conflict and Health 2014, 8:9 (3 July 2014)
Abstract (provisional)
Background
Although measles mortality has declined dramatically in Sub-Saharan Africa, measles remains a major public health problem in countries like the Democratic Republic of Congo (DRC). Here, we describe the large measles epidemic that occurred in the Democratic Republic of Congo between 2010 and 2013 using data from the national surveillance system as well as vaccine coverage surveys to provide a snapshot of the epidemiology of measles in DRC.
Methods
Standardized national surveillance data were used to describe measles cases from 2010 to 2013. Attack rates and case fatality ratios were calculated and the temporal and spatial evolution of the epidemic described. Data on laboratory confirmation and vaccination coverage surveys as a part of routine program monitoring are also presented. Findings: Between week 1 of 2010 and week 45 of 2013, a total of 294,455 cases and 5,045 deaths were reported. The cumulative attack rate (AR) was 0.4%. The Case Fatality Ratio (CFR) was 1.7% among cases reported in health structures through national surveillance. A total of 186,178 cases (63%) were under 5 years old, representing an estimated AR of 1.4% in this age group. Following the first mass vaccination campaigns, weekly reported cases decreased by 21.5%. Results of post-vaccination campaign coverage surveys indicated sub-optimal (under 95%) vaccination coverage among children surveyed.
Conclusions
The data reported here highlight the need to seek additional means to reinforce routine immunization as well as ensure the timely implementation of Supplementary Immunization Activities to prevent large and repeated measles epidemics in DRC. Although reactive campaigns were conducted in response to the epidemic, strategies to ensure that children are vaccinated in the routine system remains the foundation of measles control.

PharmacoEconomics & Outcomes News
July 2014, Volume 706, Issue 1, p 12
Men B vaccine: cost perceived as strong barrier to prescribing
K Taylor
Excerpt
Vaccine cost is a significant barrier to Australian family physicians (FPs) recommending non-funded vaccines, such as meningococcal group B (Men B) vaccine.
This is one of the findings of a survey that examine knowledge, attitudes and immunisation practices in relation to invasive meningococcal disease (IMD) and the Men B vaccine among FPs in South Australia.
The analysis of data from 523 respondents showed that high vaccine cost and perceived low socioeconomic status of the patient were identified by many respondents (59% and 61%, respectively) as strong barriers to prescribing non-funded vaccines. Most respondents (63%) were aware that a Men B vaccine was under development, and 93% agreed that this vaccine should be government-funded. The Men B vaccine for children was given the highest mean rank to receive funding out of eight currently non-funded immunisation strategies. FPs with past IMD experience were more likely to give higher priority to funding Men B vaccine for children and adults…

Special Focus Newsletters
Dengue Vaccine Initiative 10 July 2014
Sanofi Pasteur Releases Phase 3 Trial Results of Dengue Vaccine Candidate
Today, July 10, Sanofi Pasteur published in The Lancet the results of the first of two Phase 3 clinical trials for its dengue vaccine candidate — a live attenuated tetravalent vaccine. The study is a randomized, observer-blind, placebo-controlled multicenter trial involving 10,275 children aged two to 14 in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.
:: For DVI’s statement click here.